MedPath

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

Phase 3
Completed
Conditions
Non-Hodgkin's Lymphoma
Interventions
Registration Number
NCT00139841
Lead Sponsor
Cephalon
Brief Summary

SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a defined timeframe after taking rituximab (Rituxan®). Treanda will be given via 60-minute intravenous infusion on days 1 and 2 of every 21-day treatment cycle. Patients will be treated for 6 cycles unless they develop progressive disease or unacceptable toxicity. Those who continue to receive clinical benefit at end of 6 cycles may receive an additional 2 cycles. Following the end of treatment, patients will be followed for up to 2 years until disease progression or start of another anti-cancer therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
103
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Bendamustine HClbendamustine
Primary Outcome Measures
NameTimeMethod
Assess the overall response rate (ORR = CR + CRu + PR) and duration of response (DR) to a regimen of bendamustine in patients who are refractory to rituximab therapy.6 months
Secondary Outcome Measures
NameTimeMethod
• assess the safety profile of Treanda in this patient population. • assess the duration of progression-free survival (PFS). • estimate the basic pharmacokinetic parameters • assess the effects of plasma concentrations6 months

Trial Locations

Locations (40)

USC/Norris Cancer Hospital

🇺🇸

Los Angeles, California, United States

LSU Health Sciences Center, Feist Weiller Cancer Center

🇺🇸

Shreveport, Louisiana, United States

Markey Cancer Center, University of Kentucky Medical Center

🇺🇸

Lexington, Kentucky, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

University of Alabama Birmingham

🇺🇸

Birmingham, Alabama, United States

University of Colorado Cancer Center

🇺🇸

Aurora, Colorado, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Alta Bates Comprehensive Cancer Center

🇺🇸

Berkeley, California, United States

Tower Hematology and Oncology Medical Group

🇺🇸

Beverly Hills, California, United States

Dana Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Moores UCSD Cancer Center

🇺🇸

La Jolla, California, United States

Stanford University Division of Oncology

🇺🇸

Stanford, California, United States

Yale University School of Medicine

🇺🇸

New Haven, Connecticut, United States

Indiana Oncology Hematology Consultants, A Division of AHN

🇺🇸

Indianapolis, Indiana, United States

University of Michigan Cancer Center

🇺🇸

Ann Arbor, Michigan, United States

Washington University School of Medicine in St. Louis

🇺🇸

St. Louis, Missouri, United States

University of Rochester Medical Center, James P. Wilmot Cancer Center

🇺🇸

Rochester, New York, United States

Weill Cornell Cancer Care Center

🇺🇸

New York, New York, United States

University of New Mexico Cancer Research and Treatment Center

🇺🇸

Albuquerque, New Mexico, United States

Interlakes Foundation, Inc.

🇺🇸

Rochester, New York, United States

The Cleveland Clinic Foundation Taussig Cancer Center

🇺🇸

Cleveland, Ohio, United States

Duke University School of Medicine

🇺🇸

Durham, North Carolina, United States

Arlington Cancer Center

🇺🇸

Arlington, Texas, United States

Sarah Cannon Research Institute

🇺🇸

Nashville, Tennessee, United States

University of Virginia Cancer Center

🇺🇸

Charlottesville, Virginia, United States

University of Wisconsin

🇺🇸

Madison, Wisconsin, United States

British Columbia Cancer Agency

🇨🇦

Vancouver, British Columbia, Canada

Ottawa Hospital - General Campus

🇨🇦

Ottawa, Ontario, Canada

Hopital Notre-Dame du CHUM

🇨🇦

Montreal, Quebec, Canada

Queen Elizabeth Health Sciences Centre

🇨🇦

Halifax, Nova Scotia, Canada

Saskatchewan Cancer Center Agency

🇨🇦

Saskatoon, Saskatchewan, Canada

Hopital du Sacre Couer de Montreal

🇨🇦

Montreal, Quebec, Canada

Comprehensive Cancer Center - Desert Regional Medical Center

🇺🇸

Palm Springs, California, United States

Cross Cancer Institute

🇨🇦

Edmonton, Alberta, Canada

The West Clinic/ACORN

🇺🇸

Memphis, Tennessee, United States

Georgetown University Medical Center

🇺🇸

Washington, District of Columbia, United States

Hospital Espanol Auxilio Mutuo, Auxilio Mutuo Cancer Center

🇵🇷

San Juan, Puerto Rico

Nevada Cancer Institute

🇺🇸

Las Vegas, Nevada, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath